V
64.96
0.85 (1.33%)
| Previous Close | 64.11 |
| Open | 64.75 |
| Volume | 2,148,684 |
| Avg. Volume (3M) | 3,502,801 |
| Market Cap | 7,197,307,904 |
| Price / Book | 7.81 |
| 52 Weeks Range | |
| Earnings Date | 23 Oct 2024 - 28 Oct 2024 |
| Diluted EPS (TTM) | -0.930 |
| Total Debt/Equity (MRQ) | 0.12% |
| Current Ratio (MRQ) | 37.69 |
| Operating Cash Flow (TTM) | -71.94 M |
| Levered Free Cash Flow (TTM) | -39.39 M |
| Return on Assets (TTM) | -11.56% |
| Return on Equity (TTM) | -14.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Viking Therapeutics, Inc. | Bearish | Bullish |
Stockmoo Score
0.8
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -1.0 |
| Average | 0.75 |
|
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 6.03% |
| % Held by Institutions | 75.17% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Perpetual Ltd | 30 Jun 2024 | 816,808 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 138.00 (Oppenheimer, 112.44%) | Buy |
| Median | 105.00 (61.64%) | |
| Low | 80.00 (JP Morgan, 23.15%) | Buy |
| Average | 106.20 (63.49%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 62.82 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Oct 2024 | 90.00 (38.55%) | Buy | 62.64 |
| 25 Jul 2024 | 90.00 (38.55%) | Buy | 64.68 | |
| Oppenheimer | 25 Sep 2024 | 138.00 (112.44%) | Buy | 63.13 |
| Morgan Stanley | 12 Sep 2024 | 105.00 (61.64%) | Buy | 62.81 |
| JP Morgan | 11 Sep 2024 | 80.00 (23.15%) | Buy | 60.83 |
| Raymond James | 25 Jul 2024 | 118.00 (81.65%) | Buy | 64.68 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Oct 2024 | Announcement | Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD |
| 28 Aug 2024 | Announcement | Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference |
| 25 Jul 2024 | CNBC | Viking Therapeutics stock jumps nearly 30% after drugmaker moves weight loss injection to late-stage trial |
| 24 Jul 2024 | Announcement | Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
| 17 Jul 2024 | Announcement | Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |